CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study (CHARM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00645736|
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : November 22, 2011
|Condition or disease||Intervention/treatment|
|Chronic Hepatitis B||Other: No intervention|
This is a naturalistic cross-sectional study of chronic hepatitis B subjects receiving nucleoside or nucleotide antihepadnaviral therapy.
It is anticipated approximately 800 subjects will be recruited at 20 Australian sites. Data will be collected on the study subjects and analyses performed to describe factors contributing to the emergence of viral mutations in Australian patients with chronic hepatitis B.
|Study Type :||Observational|
|Actual Enrollment :||788 participants|
|Official Title:||Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy|
|Study Start Date :||February 2008|
|Primary Completion Date :||October 2008|
|Study Completion Date :||November 2008|
Other: No intervention
- Descriptive statistics for clinical and viral characteristics of the study population [ Time Frame: Single timepoint (blood draw) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00645736
|Gilead Sciences Pty Ltd|
|East Melbourne, Victoria, Australia, 3002|
|Study Director:||Howard Wraight||Gilead Sciences Pty Ltd|